Entrada Therapeutics, Inc. (TRDA) analyst actions
Rating and price-target actions on TRDA in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the TRDA overview →
4 measured TRDA analyst action events.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 3 at the Top Dose of 18 mg/kg in Entrada Therapeutics’ ELEVATE-44-201 Study | Press release | +0.85% | -2.98% | |
| Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 10 mg/kg in Entrada Therapeutics’ ELEVATE-45-201 Study | Press release | -0.88% | -2.35% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Entrada Therapeutics, Inc. (TRDA) And Encourages Shareholders to Reach Out | Press release | -0.72% | -1.34% | |
| Independent Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 12 mg/kg in Entrada Therapeutics’ ELEVATE-44-201 Study | Press release | +0.46% | +0.82% |
Keep exploring
More TRDA: earnings → · SEC filings → · TRDA overview →